|
" Prolactin : "
E Fluckiger
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
729742
|
| Doc. No
|
:
|
b549497
|
| Main Entry
|
:
|
E Fluckiger
|
| Title & Author
|
:
|
Prolactin : : physiology, pharmacology and clinical findings.\ E Fluckiger
|
| Publication Statement
|
:
|
[Place of publication not identified]: Springer, 2012
|
| ISBN
|
:
|
3642817211
|
|
|
:
|
: 9783642817212
|
| Contents
|
:
|
1 Prolactin; Synthesis, Fate and Actions.- 1.1 Molecular Structure.- 1.2 Synthesis, Storage and Secretion by the Pituitary.- 1.3 Extrapituitary Sites of Prolactin Synthesis.- 1.4 Prolactin in the Body Fluids; Metabolic Clearance.- 1.5 Prolactin Receptors.- 1.6 The Spectrum of Actions.- 1.6.1 Effects on the Mammary Gland (Lactation).- 1.6.2 Prolactin and the Mammary Cancer Problem.- 1.6.3 Effects on the Ovary.- 1.6.4 Effects on the Testis.- 1.6.5 Prolactin and Hypogonadism.- 1.6.6 Accessory Glands.- 1.6.7 Effects on the Adrenal Cortex.- 1.6.8 Effects on the Excretory Kidney.- 1.6.9 Effects on Fluid Transport in Nonrenal Organs.- 1.6.10 Effects on the Liver.- 1.6.11 Prolactin and Vitamin D3 Metabolism.- 1.6.12 Effects on Carbohydrate and Fat Metabolism.- 1.6.13 Prolactin and Fetal Lung Maturation.- 2 Control of Prolactin Secretion.- 2.1 Physiologic Aspects.- 2.1.1 Patterns of Prolactin Secretion.- 2.1.2 Regulatory Factors.- 2.2 Pharmacologic Aspects.- 2.2.1 Inhibition by Dopaminergic Mechanisms.- 2.2.1.1 Directly Acting Drugs.- 2.2.1.2 Indirectly Acting Drugs.- 2.2.2 Inhibition by Serotoninergic Mechanisms.- 2.2.3 Inhibition by Cholinergic Mechanisms.- 2.2.4 Inhibition via Gaba-ergic Mechanisms.- 2.2.5 Miscellaneous Approaches to Prolactin Suppression.- 2.2.5.1 Inhibition of Prostaglandin Synthesis.- 2.2.5.2 Steroids and Antagonists.- 2.3 References (also for Chap. 1).- 3 Physiology and Pharmacology of Human Lactation.- 3.1 Preparation of Mammary Tissue for Lactation: Hormonal Mechanisms.- 3.2 Maternofetal Correlations; Concentration of Lactogens in a Three-Compartment System Throughout Pregnancy.- 3.3 Biologic Effects of Lactogenic Hormones During Pregnancy.- 3.4 Nyctohemeral PRL Rhythm During Pregnancy and Effect of TRH and Dopaminergic Blockade.- 3.5 Mechanisms of Milk Secretion (Lactogenesis); Maintenance of Lactation (Lactopoiesis).- 3.5.1 The Suckling Reflex: Effect on Prolactin and Milk Production.- 3.5.2 Role of Neurotransmitters in the Initiation and Maintenance of Lactation.- 3.6 Impact of Lactation on Fertility.- 3.6.1 The Hypothalamic-Pituitary-Ovarian Axis in the Early Postpartum.- 3.6.2 Lactation and Fertility in Late Puerperium.- 3.6.3 Mechanisms of Lactational Infertility: Effect of Suckling.- 3.7 Psychosomatic Aspects of Human Lactation.- 3.8 Postpartum Hypoprolactinemia.- 3.9 Suppression of Puerperal Lactation.- 3.9.1 Suppression of Milk Secretion by Physical Measures.- 3.9.2 Inhibition of Lactation with Estrogens.- 3.9.3 Specific Prolactin Suppression with Dopamine Agonists.- 3.9.4 Lactation Suppression with Nonergot Drugs.- 3.10 References.- 4 Nontumoral Hyperprolactinemia.- 4.1 Tests of Lactotrope Cell Function.- 4.1.1 Dopamine (DA) Antagonists and Effect of TRH.- 4.1.2 Dopaminergic Drugs.- 4.1.3 Insulin Hypoglycemia.- 4.1.4 Water Load Test.- 4.2 Factors Influencing Basal Prolactin Secretion in the Clinical Practice.- 4.2.1 Chronobiologic Fluctuations.- 4.2.2 Effect of Stress and Other Factors.- 4.3 Physiopathology of Functional Hyperprolactinemia.- 4.3.1 Effect of Hyperprolactinemia in Women.- 4.3.1.1 Mechanism of Cyclic Disturbances Induced by Hyperprolactinemia.- 4.3.1.2 Effect of Hyperprolactinemia on the Ovary.- 4.3.1.3 Effect of Hyperprolactinemia on Gonadotropin Release.- 4.3.1.4 Adrenal Function in Hyperprolactinemia.- 4.3.1.5 Hyperprolactinemia and the Polycystic Ovary Syndrome (PCO).- 4.3.1.6 Prolactin and Premature Menopause.- 4.3.1.7 Diabetogenic Effect of Prolactin.- 4.3.1.8 The Psychogenic Component of Hyperprolactinemia.- 4.3.2 Effect of Hyperprolactinemia in Male Subjects.- 4.4 Control of Lactotrope Cell Function in Pathologic Hyperprolactinemia.- 4.4.1 Effect of Dopaminergic Blockade and Stimulation with TRH.- 4.4.2 Orcadian Rhythm of Prolactin in the Galactorrhea Syndromes.- 4.5 Incidence of Hyperprolactinemia.- 4.6. Inappropriate Prolactin Secretion: A Classification Under Consideration of Etiologic Factors.- 4.6.1 Historical Background.- 4.6.2 Drugs as Causative Factors.- 4.6.3 Hyperprolactinemia Associated with Other Endocrinopathies.- 4.6.4 Association of Hyperprolactinemia with Nonendocrine Diseases.- 4.6.5 Hyperprolactinemia Through Disturbances of Neural Pituitary Control.- 4.7 Clinical and Biochemical Effect of Inappropriate Prolactin Secretion.- 4.8 Natural History of Galactorrhea Syndromes.- 4.9 Medical Therapy of Nontumorous Prolactin-Dependent Conditions.- 4.9.1 Dopaminergic Drugs: Bromocriptine.- 4.9.1.1 Galactorrhea-Amenorrhea Syndrome.- 4.9.1.2 Hyperprolactinemia and Inappropriate Luteal Phase.- 4.9.1.3 Hyperprolactinemic Anovulation Without Galactorrhea.- 4.9.1.4 Metrorrhagia with Elevated PRL: Response to Bromocriptine.- 4.9.1.5 Effect of Bromocriptine on the Anovulation of Polycystic Ovary Syndrome with Hyperprolactinemia.- 4.9.1.6 Miscellaneous Effects of Bromocriptine on Reproduction.- 4.9.2 Impact of Bromocriptine Treatment on Pregnancy and Fetal Development.- 4.9.3 Treatment of Male Hyperprolactinemia with Bromocriptine.- 4.10 Effect of Other Ergot Derivatives on Prolactin Secretion.- 4.11 Effect of Nonergot Dopamine Agonists on Prolactin Secretion.- 4.12 References.- 5 Pituitary Prolactinomas.- 5.1 Morphology of the Prolactin Secreting Cell.- 5.1.1 Normal Lactotroph.- 5.1.2 Prolactinomas.- 5.2 Pathophysiology of Prolactinomas.- 5.2.1 Prolactin Secretion.- 5.2.1.1 Basal Prolactin Levels.- 5.2.1.2 Hypothalamic Hypophyseotropic Hormones.- 5.2.1.3 Insulin Hypoglycemia.- 5.2.1.4 Dopamine Antagonists.- 5.2.1.5 Dopamine Agonists.- 5.2.2 Pituitary Function.- 5.2.2.1 Growth Hormone Secretion.- 5.2.2.2 Gonadotropin Secretion.- 5.2.2.3 Thyrotropin Secretion.- 5.2.2.4 ACTH Secretion.- 5.2.2.5 Posterior Pituitary Function.- 5.2.3 Local Tumor Symptoms.- 5.2.3.1 Sella Turcica.- 5.2.3.2 Chiasma Syndrome.- 5.3 Clinical Signs and Diagnosis of Hyperprolactinemia Due to Prolactinomas.- 5.3.1 Females with Hyperprolactinemia.- 5.3.1.1 Microprolactinomas.- 5.3.1.1.1 Incidence.- 5.3.1.1.2 Prolactin Secretion.- 5.3.1.1.3 Clinical Signs.- 5.3.1.2 Macroprolactinomas.- 5.3.1.2.1 Incidence.- 5.3.1.2.2 Clinical Signs.- 5.3.1.3 Mixed Adenomas.- 5.3.2 Male Patients with Hyperprolactinemia.- 5.3.2.1 Incidence and Clinical Signs of Macroprolactinomas.- 5.3.2.2 Mixed Adenomas.- 5.4 Therapy of Prolactinomas.- 5.4.1 Medical Treatment.- 5.4.1.1 Microprolactinomas.- 5.4.1.2 Macroprolactinomas.- 5.4.1.3 Antiproliferative Effect of Ergot Alkaloid Derivatives on Prolactinoma Growth.- 5.4.2 Operative Treatment.- 5.4.3 Radiotherapy.- 5.5 Pregnancy and Prolactinoma.- 5.5.1 Clinical Course of Prolactinomas During Pregnancy.- 5.5.2 Treatment of Females with Prolactinomas Seeking Fertility.- 5.5.2.1 Surgery.- 5.5.2.2 Medical Therapy.- 5.5.2.3 Treatment of Local Tumor Complications During Pregnancy.- 5.6 References.
|
| LC Classification
|
:
|
QP572.P74E358 2012
|
| Added Entry
|
:
|
E Fluckiger
|
| |